

ASX ANNOUNCEMENT

Analytica Provides Interim Update on Sales Performance

- Encouraging early growth in sales direct to consumers
- Clinician support driving increased adoption

4 June 2015: BRISBANE, Australia - Analytica (ASX: ALT), manufacturer of the PeriCoach®, is pleased to announce encouraging early sales results for the company's pelvic floor training system. PeriCoach® has only been marketed and available in Australia for both major operating systems since late January. FDA clearance came 2 months earlier than anticipated and logistics has only just permitted pre-order sales in the USA (marketing commences late in June), the company has reported sales of this unique system is growing demonstrating solid evidence of acceptance amongst women (see Figure 1).




Figure 1: Cumulative Sales to Clinician (red) (excludes pre 2015) Patients (blue) Total (green)

Importantly, the PeriCoach system is being presented at global clinical conferences where it was widely accepted by clinicians including General Practitioners, Gynaecologists and Urogynaecologists (in many cases clinicians purchased the system for personal use or for office demonstration purposes). Doctors and Clinicians awareness of the capability of the PeriCoach® should contribute positively to the patient buying decision.

As PeriCoach® uptake is increasing, more data is being generated. Analysis of this data demonstrates that the PeriCoach is making a significant difference in women's lives. A sample of these results from four anonymised, paying patients are graphed in Figure 2.



Figure 2: Improvement from starting strength with time - 4 Patients.



Doctors attending the Sydney General Practitioner Conference and Exhibition (GPCE) on the weekend 22-24th May showed considerable interest in these results and that they can track their patient's progress. "PeriCoach joined us for the 2015 Sydney GPCE and we were pleased to see both high numbers and levels of engagement from GPs. UI is an area we know GPs need to gain more understanding and we were pleased to see such success and value add to our GPs that PeriCoach offered." Conference organisers, Reed Medical Education.

Data is a key differentiator of the PeriCoach system with its 3 muscle sensors transmitting bulk data to cloud based storage, making it available for super computer analysis. For patients, the data is simplified to provide guidance and encouragement. Doctors are able to drill down into their patients exercise results. Specialist and researchers have data never available before. With unique ability to update exercise programs remotely this data can ensure PeriCoach is constantly evolving delivering exceptional results. Support for the adoption of PeriCoach as a validated system for treating female urinary incontinence has been underpinned by US Healthcare Specialists who will be featured in the US release.

Analytica's Chairman, Dr Michael Monsour, commented "Shareholders support last year to investment in development and marketing foundations is now showing results. We are very pleased with these early sales indications. For me, attending the GPCE in Sydney and experiencing the interest and enthusiasm of GP's was invigorating. Feedback from clinicians and patients has been very encouraging, and we are seeing adoption rates increasing on a daily basis"



For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark clearance. The product has USFDA 510(k) clearance in the USA. Product launches are anticipated in Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.

